Ahead of the vote at the extraordinary general meeting, Sandoz CEO Richard Saynor said the new company is eyeing the launch of at least five additional biologic drugs over the longer term.
Tag Archive for: biologic drugs
Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland’s Novartis works to enhance its investor appeal ahead of its market debut next month.
Drugmakers Boehringer Ingelheim, Sandoz and Organon are expected to launch their biosimilars on Saturday, adding to U.S. competition for the drug that started when Amgen released its copy in January. Germany’s Fresenius plans to release its copycat version on Monday, according to the company.
“We believe that subcutaneous formulation has the potential to be novel, non-obvious and useful, which means we would get a new patent for it,” according to Merck CFO Caroline Litchfield.
The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co’s Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.
Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.
